Cannabis Rescheduling Momentum Persists Through DOJ Leadership Chaos
Federal marijuana rescheduling process continues advancing despite ongoing uncertainty at Department of Justice under Trump administration transition.
The federal cannabis rescheduling process maintains forward momentum even as the Department of Justice experiences leadership upheaval during the Trump administration transition. This regulatory persistence signals institutional commitment to the rescheduling review that began under the Biden administration, suggesting the process has gained enough bureaucratic inertia to weather political turbulence.
The rescheduling initiative, which would move cannabis from Schedule I to Schedule III under the Controlled Substances Act, represents the most significant federal cannabis policy shift in decades. Moving to Schedule III would eliminate the 280E tax burden that currently prevents cannabis companies from deducting standard business expenses, potentially boosting sector-wide margins by 15-30% according to industry estimates.
Major multi-state operators including Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) stand to benefit substantially from 280E relief. These companies currently face effective tax rates exceeding 70% in some cases, with rescheduling potentially unlocking hundreds of millions in additional cash flow across the sector. The tax relief would particularly benefit high-volume operators with significant operational expenses.
The regulatory advancement occurs against a backdrop of state-level expansion, with Ohio launching adult-use sales and additional states preparing recreational programs. This dual momentum of federal rescheduling and state market growth creates a favorable environment for cannabis equity valuations, which remain depressed compared to traditional consumer goods companies despite similar revenue multiples.
While DOJ leadership changes typically introduce policy uncertainty, the rescheduling process involves multiple federal agencies including the Drug Enforcement Administration and Health and Human Services. This multi-agency structure provides procedural stability that insulates the review from immediate political interference, supporting continued progress regardless of short-term personnel shifts at Justice Department leadership levels.